OTCPK:IZOZ.F

Stock Analysis Report

Executive Summary

Izotropic Corporation, a research and development company, commercializes diagnostic products for breast cancer.

Snowflake

Adequate balance sheet with poor track record.

Share Price & News

How has Izotropic's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IZOZ.F's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

IZOZ.F

2.4%

US Medical Equipment

0.9%

US Market


1 Year Return

n/a

IZOZ.F

23.9%

US Medical Equipment

16.8%

US Market

Return vs Industry: Insufficient data to determine how IZOZ.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how IZOZ.F performed against the US Market.


Shareholder returns

IZOZ.FIndustryMarket
7 Day0%2.4%0.9%
30 Day-22.0%3.6%4.5%
90 Dayn/a2.2%6.2%
1 Yearn/a25.0%23.9%19.4%16.8%
3 Yearn/a90.3%84.5%47.5%38.0%
5 Yearn/a117.4%93.9%62.0%44.1%

Price Volatility Vs. Market

How volatile is Izotropic's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Izotropic undervalued compared to its fair value and its price relative to the market?

23.46x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IZOZ.F's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IZOZ.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IZOZ.F is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: IZOZ.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IZOZ.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IZOZ.F is overvalued based on its PB Ratio (23.5x) compared to the US Medical Equipment industry average (4x).


Next Steps

Future Growth

How is Izotropic forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Izotropic has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Izotropic performed over the past 5 years?

38.2%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: IZOZ.F has high quality earnings.

Growing Profit Margin: IZOZ.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if IZOZ.F's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare IZOZ.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IZOZ.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.3%).


Return on Equity

High ROE: IZOZ.F has a negative Return on Equity (-160.76%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Izotropic's financial position?


Financial Position Analysis

Short Term Liabilities: IZOZ.F's short term assets (CA$304.5K) exceeds its short term liabilities (CA$25.9K)

Long Term Liabilities: IZOZ.F has no long term liabilities


Debt to Equity History and Analysis

Debt Level: IZOZ.F is debt free.

Reducing Debt: IZOZ.F had no debt 5 years ago.


Balance Sheet

Inventory Level: IZOZ.F has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if IZOZ.F's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IZOZ.F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IZOZ.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of -33.1% each year


Next Steps

Dividend

What is Izotropic's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate IZOZ.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IZOZ.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IZOZ.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IZOZ.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IZOZ.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Izotropic's salary, the management and board of directors tenure and is there insider trading?

2.5yrs

Average board tenure


CEO

Bob Thast (65yo)

3.5yrs

Tenure

0

Mr. Robert Louis Thast, also known as Bob, has been the President and Chief Executive Officer of Maxore Minerals Corp. since March 15, 2007. He has been the President of Thast Projects Inc. since April 199 ...


Board Age and Tenure

2.5yrs

Average Tenure

Experienced Board: IZOZ.F's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 69.1%.


Management Team

  • Bob Thast (65yo)

    CEO, President

    • Tenure: 3.5yrs
  • Jody Bellefleur

    Chief Financial Officer

    • Tenure: 1.3yrs
    • Compensation: CA$10.76k
  • Marshall Severyn

    VP of Marketing & Director

    • Tenure: 2.5yrs

Board Members

  • Ralph Proceviat (69yo)

    Director

    • Tenure: 0yrs
  • Bob Thast (65yo)

    CEO, President

    • Tenure: 3.5yrs
  • John Boone

    Independent Director

    • Tenure: 2.5yrs
  • Ali Sodagar

    Independent Director

    • Tenure: 2.5yrs
  • Marshall Severyn

    VP of Marketing & Director

    • Tenure: 2.5yrs
  • Karen Lindfors

    Member of Advisory Board

    • Tenure: 0yrs

Company Information

Izotropic Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Izotropic Corporation
  • Ticker: IZOZ.F
  • Exchange: OTCPK
  • Founded: 2016
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$6.668m
  • Listing Market Cap: CA$5.010m
  • Shares outstanding: 23.82m
  • Website: https://izocorp.com

Location

  • Izotropic Corporation
  • 800 – 15355 24th Avenue
  • Suite 424
  • Surrey
  • British Columbia
  • V4A 2H9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IZOCNSX (Canadian National Stock Exchange)YesCommon SharesCACADJun 2018
IZOZ.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJun 2018
1R3DB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2018

Biography

Izotropic Corporation, a research and development company, commercializes diagnostic products for breast cancer. It develops and commercializes next generation 3-D breast CT imaging technology for early di ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/21 01:11
End of Day Share Price2019/10/31 00:00
Earnings2019/07/31
Annual Earnings2019/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.